An upstate New York pharmaceutical sales representative was among three whistle-blowers to supply information to federal prosecutors leading to a $193 million settlement with makers of the Lidoderm ...

SAN FRANCISCO (CN) - A federal judge on Thursday finalized two class action settlements worth $270 million, ending four years of litigation over an alleged antitrust conspiracy to keep a generic form ...

Under the settlement agreement, the company inked a Deferred Prosecution Agreement (:DPA) with the United States Department of Justice. The duration of the DPA is up to 2 years and 6 months. In a ...

SAN FRANCISCO (CN) – Rejecting arguments that damages would be too arduous to calculate on a class-wide basis, a federal judge this week certified two classes in a multidistrict antitrust suit over ...

Endo Pharmaceuticals became the latest drugmaker to ink an off-label marketing settlement, paying $192.7 million to resolve charges it promoted pain patch Lidoderm for unapproved uses. According to a ...

The US Department of Health and Human Services (HHS) has issued Endo Pharmaceuticals a subpoena regarding the promotion of its post-shingles pain patch Lidoderm. The subpoena requests documents from ...

AUSTIN, TX—Arash Nafissi, DO, and colleagues of Hospital for Joint Disease, New York University, report that placing a topical Lidoderm patch provides an effective adjunct treatment in post-operative ...

PHILADELPHIA (Legal Newsline) – Endo Health Solutions Inc. and its subsidiary, Endo Pharmaceuticals, have agreed to a $171.9 million settlement with the federal government to resolve off-label ...

Pharma has its latest pay-for-delay settlement. In a pair of deals with two plaintiff classes over generic Lidoderm delays, Endo, Teva and Japanese drugmaker Teikoku Seiyaku have agreed to fork over ...

Watson Pharma intends to begin shipments of its generic version of Lidoderm in September 2013 per the terms of its settlement agreement with Endo. Watson believes it is entitled to a 180-day period of ...

SAN FRANCISCO (MarketWatch) -- Endo Pharmaceuticals Holdings Inc. after Monday's closing bell said that net sales of Lidoderm, its largest-selling product, are expected to be below underlying demand ...